The Zhitong Finance App learned that Yamato released a research report saying that Sinopharm Holdings (01099.HK)'s performance in the first half of the year was slightly lower than expected and maintained a “holding” rating. The target price was reduced from HK$18 to HK$17.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.